MULTIPLE SCLEROSIS (MS) is a multifocal, demyelinating disease of the central nervous system (CNS) that is characterized by recurrent or chronically progressive neurologic dysfunction. Multiple sclerosis is first recognized by clinicians as relapsing-remitting MS (RRMS) in most patients.
1 Relapsing-remitting MS is characterized by well-defined disease relapses followed by periods of full recovery or with residual deficit on recovery. Although a lack of disease progression between relapses is seen, RRMS may be ongoing subclinically before clinical manifestations. Secondary-progressive MS starts as RRMS and is characterized by gradual disease progression with or without relapses, minor remissions, and plateaus.
2 Natural history data suggest that of patients with RRMS at onset, the disease will transform to progressive MS after 10 years in more than 50% and after 25 years in approximately 90%.
1